Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes

被引:8
|
作者
Sand, Kristoffer [1 ]
Theorell, Jakob [2 ]
Bruserud, Oystein [1 ,3 ]
Bryceson, Yenan T. [1 ,2 ]
Kittang, Astrid Olsnes [1 ,3 ]
机构
[1] Univ Bergen, Dept Clin Sci, Bergen, Norway
[2] Karolinska Inst, Karolinska Univ Hosp Huddinge, Dept Med, Ctr Infect Med, Stockholm, Sweden
[3] Haukeland Hosp, Div Hematol, Dept Med, Jonas Lies Vei 65, N-5021 Bergen, Norway
关键词
Myelodysplastic syndromes; Cytotoxic T lymphocytes; CD57; CX3CR1; Granzyme B; Adhesion; LYTIC GRANULE EXOCYTOSIS; BONE-MARROW; ELEVATED EXPRESSION; CYTOLYTIC ACTIVITY; APLASTIC-ANEMIA; CELL RESPONSE; SYNDROME MDS; ANTIGEN; CANCER; AZACITIDINE;
D O I
10.1007/s00262-016-1865-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Myelodysplastic syndromes (MDS) are a group of clonal bone marrow disorders, with dysplasia, cytopenias and increased risk of progression to acute myeloid leukemia. A dysregulated immune system precipitates MDS, and to gain insights into the relevance of cytotoxic T lymphocyte (CTL) in this process, we examined the frequency and function of CX3CR1- and CD57-positive T lymphocytes from MDS patients. Peripheral blood and/or bone marrow samples from 31 MDS patients and 12 healthy controls were examined by flow cytometry. Expression of cytotoxic granule constituents, immunological co-receptors, adhesion molecules and markers of activation were quantified on unstimulated lymphocytes. Degranulation, cytotoxicity and conjugate formation with target cells following co-culture of CTL with target cell lines or autologous bone marrow-derived CD34(+) cells were quantified by flow cytometry. CX3CR1 expression was increased in bone marrow from high-risk MDS patients compared to healthy controls. Expression of CD57 and CX3CR1 was closely correlated, identifying a CTL subset with high cytotoxic capacity. In vitro, TCR-induced redirected cytotoxicity was markedly decreased for high-risk MDS patients compared to controls. CTL from MDS patients with the lowest target cell cytotoxicity had reduced expression of adhesion molecules and formed fewer conjugates with target cells. Although phenotypically defined CTL numbers were increased in the bone marrow of MDS patients, we found that CTL from high-risk MDS patients exhibited a lower TCR-induced redirected cytotoxic capacity. Thus, decreased T cell cytotoxicity seems related to reduced adhesion to target cells and may contribute to impaired anti-leukemic immune surveillance in MDS.
引用
收藏
页码:1135 / 1147
页数:13
相关论文
共 50 条
  • [1] Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes
    Kristoffer Sand
    Jakob Theorell
    Øystein Bruserud
    Yenan T. Bryceson
    Astrid Olsnes Kittang
    [J]. Cancer Immunology, Immunotherapy, 2016, 65 : 1135 - 1147
  • [2] Treatment of patients with high-risk myelodysplastic syndromes
    Gattermann, Norbert
    Kuendgen, Andrea
    Germing, Ulrich
    [J]. CANCER TREATMENT REVIEWS, 2007, 33 : S64 - S68
  • [3] Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes
    Saft, Leonie
    Bjorklund, Elisabet
    Berg, Elisabeth
    Hellstrom-Lindberg, Eva
    Porwit, Anna
    [J]. LEUKEMIA RESEARCH, 2013, 37 (03) : 266 - 273
  • [4] Treatment of high-risk myelodysplastic syndromes
    Fenaux, Pierre
    [J]. HEMATOLOGIE, 2006, 12 : 12 - 13
  • [5] Treating high-risk myelodysplastic syndromes
    Ades, Lionel
    [J]. BULLETIN DU CANCER, 2023, 110 (11) : 1162 - 1167
  • [6] Management of high-risk myelodysplastic syndromes
    Pisani, FD
    Rainaldi, A
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 40 (03) : 215 - 228
  • [7] DECITABINE IN TREATMENT OF PATIENTS WITH INTERMEDIATEOR HIGH-RISK MYELODYSPLASTIC SYNDROMES
    Kalinichenko, E.
    Ponteleeva, I.
    Fiodarava, A.
    Iskrov, I.
    Uss, A.
    [J]. LEUKEMIA RESEARCH, 2017, 55 : S71 - S72
  • [8] High-risk myelodysplastic syndromes in hypomethylants failure
    Gardin, Claude
    [J]. HEMATOLOGIE, 2010, 16 : 24 - 28
  • [9] Histopathology in the diagnosis of high-risk myelodysplastic syndromes
    Kayano, Hidekazu
    [J]. JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2018, 58 (02) : 51 - 60
  • [10] Azacitidine delivers dramatic results in patients with high-risk myelodysplastic syndromes
    Fenaux, P.
    Mufti, G. J.
    Hellstrom-Lindberg, E.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (04) : 395 - 395